Abstract
This chapter focuses on the role of sphingolipids in the regulation of sterol-regulatory element binding protein (SREBP) dependent lipid synthesis and ATP-binding cassette protein ABCA1 and ABCG1 mediated lipid efflux, key regulators of cellular lipid homeostasis. Sphingolipid synthesis activates SREBPs independently of whether sphingolipid synthesis occurs through recycling or de novo pathways. SREBPs are major transcription factors of lipid metabolism that regulate more than 30 genes of cholesterol, fatty acid and phospholipid synthetic enzymes and they required NADPH cofactors. SREBPs are downstream of sphingolipid synthesis and do not regulate activity of sphingolipid synthetic enzymes. Cells that cannot synthesize sphingolipids fail to increase SREBP in response to lipid depletion. Similar mechanisms are found in D. melanogaster in which SREBP activity depends on expression of a ceramide synthase analog. SREBP is inhibited by its end products cholesterol and unsaturated fatty acids. Ceramide decreases SREBP by inhibiting sphingolipid synthesis. Molecular mechanisms of regulation are related to the effect of sphingolipids on intracellular trafficking but are overall not clear. Several groups have investigated the effect of sphingolipids in the regulation of cholesterol efflux receptors ABCA1 and ABCG1, major regulators of plasma high-density lipoprotein (HDL) concentration, an important anti-atherogenic lipoprotein. Data indicate an inverse relationship between sphingolipid de novo synthesis and cholesterol efflux. Inhibition of sphingolipid de-novo synthesis increases ABCA1 mediated cholesterol efflux independent of sphingomyelin. Potential mechanisms include the physical interaction of subunit 1 of serine-palmitoyl transferase (SPT), the rate limiting enzyme of de-novo sphingolipid synthesis, with ABCA1. ABCG1 mediated efflux, in contrast, is dependent on sphingomyelin mass. Animal studies support the findings made in cultured cells. Inhibition of sphingolipid de novo synthesis increases anti-atherogenic lipoproteins and decreases atherosclerosis in mouse models. Together, manipulation of sphingolipid synthetic pathways is a potentially promising therapeutic target for treatment of low-HDL dyslipidemia and atherosclerosis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Futerman AH, Riezman H. The ins and outs of sphingolipid synthesis. Trends Cell Biol 2005; 15:312–318.
Hannun YA, Obeid LM. The Ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J Biol Chem 2002; 277:25847–25850.
Hua X, Yokoyama C, Wu J et al. SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element. Proc Natl Acad Sci USA 1993; 90:11603–11607.
Wang X, Sato R, Brown MS et al. SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis. Cell 1994; 77:53–62.
Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109:1125–1131.
Horton JD, Shah NA, Warrington JA et al. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci USA 2003; 100:12027–12032.
Dobrosotskaya IY, Seegmiller AC, Brown MS et al. Regulation of SREBP processing and membrane lipid production by phospholipids in Drosophila. Science 2002; 296:879–883.
Repa JJ, Liang G, Ou J et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 2000; 14:2819–2830.
Sakai J, Duncan EA, Rawson RB et al. Sterol-regulated release of SREBP-2 from cell membranes requires two sequential cleavages, one within a transmembrane segment. Cell 1996; 85:1037–1046.
Worgall TS, Juliano RA, Seo T et al. Ceramide synthesis correlates with the posttranscriptional regulation of the sterol-regulatory element-binding protein. Arterioscler Thromb Vasc Biol 2004; 24:943–948.
Bauer R, Voelzmann A, Breiden B et al. Schlank, a member of the ceramide synthase family controls growth and body fat in Drosophila. EMBO J 2009; 28(23):3706–3716.
Ishitsuka R, Hirabayashi Y, Kobayashi T. Glycosphingolipid deficiency increases the sterol regulatory element-mediated gene transcription. Biochem Biophys Res Commun 2009; 378:240–243.
Gable K, Slife H, Bacikova D et al. Tsc3p is an 80-amino acid protein associated with serine palmitoyltransferase and required for optimal enzyme activity. J Biol Chem 2000; 275:7597–7603.
Hornemann T, Richard S, Rütti MF et al.Cloning and initial characterization of a new subunit for mammalian serine-palmitoyltransferase. J Biol Chem 2006; 281:37275–37281.
Han G, Gupta SD, Gable K et al. Identification of small subunits of mammalian serine palmitoyltransferase that confer distinct acyl-CoA substrate specificities. Proc Natl Acad Sci USA 2009; 106:8186–8191.
Hornemann T, Penno A, Rütti MF et al. The SPTLC3 subunit of serine palmitoyltransferase generates short chain sphingoid bases. J Biol Chem 2009; 284:26322–26330.
Merrill AH Jr, Sullards MC, Allegood JC et al. Sphingolipidomics: high-throughput, structure-specific and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. Methods 2005; 36:207–224.
Venkataraman K, Riebeling C, Bodennec J et al. Upstream of growth and differentiation factor 1 (uog1), a mammalian homolog of the yeast longevity assurance gene 1 (LAG1), regulates N-stearoyl-sphinganine (C18-(dihydro)ceramide) synthesis in a fumonisin B1-independent manner in mammalian cells. J Biol Chem 2002; 277:35642–35649.
Pewzner-Jung Y, Ben-Dor S, Futerman AH. When do lasses (longevity assurance genes) become CerS (ceramide synthases)?: Insights into the regulation of ceramide synthesis. J Biol Chem 2006; 281:25001–25005.
Hanada K, Kumagai K, Yasuda S et al. Molecular machinery for nonvesicular trafficking of ceramide. Nature 2003; 426:803–809.
Hanada K. Discovery of the molecular machinery CERT for endoplasmic reticulum-to-Golgi trafficking of ceramide. Mol Cell Biochem 2006; 286:23–31.
Kawano M, Kumagai K, Nishijima M et al. Efficient trafficking of ceramide from the endoplasmic reticulum to the Golgi apparatus requires a VAMP-associated protein-interacting FFAT motif of CERT. J Biol Chem 2006; 281:30279–30288.
Huitema K, van den Dikkenberg J, Brouwers JF et al. Identification of a family of animal sphingomyelin synthases. EMBO J 2004; 23:33–44.
Tafesse FG, Ternes P, Holthuis JC. The multigenic sphingomyelin synthase family. J Biol Chem 2006; 281:29421–29425.
Seegmiller AC, Dobrosotskaya I, Goldstein JL et al. The SREBP pathway in Drosophila: regulation by palmitate, not sterols. Dev Cell 2002; 2:229–238.
Kunte AS, Matthews KA, Rawson RB. Fatty acid auxotrophy in Drosophila larvae lacking SREBP. Cell Metab 2006; 3:439–448.
Hojjati MR, Li Z, Jiang XC. Serine palmitoyl-CoA transferase (SPT) deficiency and sphingolipid levels in mice. Biochim Biophys Acta 2005; 1737:44–51.
Hojjati MR, Li Z, Zhou H et al. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J Biol Chem 2005; 280:10284–10289.
Park TS, Panek RL, Mueller SB et al. Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 2004; 110:3465–3471.
Park TS, Panek RL, Rekhter MD et al. Modulation of lipoprotein metabolism by inhibition of sphingomyelin synthesis in ApoE knockout mice. Atherosclerosis 2006; 189:264–272.
Park TS, Rosebury W, Kindt EK et al. Serine palmitoyltransferase inhibitor myriocin induces the regression of atherosclerotic plaques in hyperlipidemic ApoE-deficient mice. Pharmacol Res 2008; 58:45–51.
Ozbay T, Rowan A, Leon A et al. Cyclic adenosine 5′-monophosphate-dependent sphingosine-1-phosphate biosynthesis induces human CYP17 gene transcription by activating cleavage of sterol regulatory element binding protein 1. Endocrinology 2006; 147:1427–1437.
Worgall TS, Sturley SL, Seo T et al. Polyunsaturated fatty acids decrease expression of promoters with sterol regulatory elements by decreasing levels of mature sterol regulatory element-binding protein. J Biol Chem 1998; 273:25537–25540.
Johnson RA, Hamilton JA, Worgall TS et al. Free fatty acids modulate intermembrane trafficking of cholesterol by increasing lipid mobilities: novel 13C NMR analyses of free cholesterol partitioning. Biochemistry 2003; 42:1637–1645.
Kucerka N, Marquardt D, Harroun TA et al. The functional significance of lipid diversity: orientation of cholesterol in bilayers is determined by lipid species. J Am Chem Soc 2009; 131:16358–16359.
Worgall TS et al. Fatty acids can regulate sterol-regulatory element dependent gene transcription through ceramide metabolism. Circulation 2000; 102:II 360:1769.
Scheek S, Brown MS, Goldstein JL. Sphingomyelin depletion in cultured cells blocks proteolysis of sterol regulatory element binding proteins at site 1. Proc Natl Acad Sci USA 1997; 94:11179–11183.
Subbaiah PV, Sowa JM, Singh DK. Sphingolipids and cellular cholesterol homeostasis. Effect of ceramide on cholesterol trafficking and HMG CoA reductase activity. Arch Biochem Biophys 2008; 474:32–38.
Schaefer EJ, Lamon-Fava S, Ordovas JM et al. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res 1994; 35:871–882.
Lewington S, Whitlock G, Clarke R et al. Blood cholesterol and vascular mortality by age, sex and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370:1829–1839.
Barter P, Gotto AM, LaRosa JC et al. HDL cholesterol, very low levels of LDL cholesterol and cardiovascular events. N Engl J Med 2007; 357:1301–1310.
Bodzioch M, Orsó E, Klucken J et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 1999; 22:347–351.
Brooks-Wilson A, Marcil M, Clee SM et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 1999; 22:336–345.
Kennedy MA, Barrera GC, Nakamura K et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab 2005; 1:121–131.
Wang N, Lan D, Chen W et al. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA 2004; 101:9774–9779.
Glaros EN, Kim WS, Quinn CM et al. Glycosphingolipid accumulation inhibits cholesterol efflux via the ABCA1/apolipoprotein A-I pathway: 1-phenyl-2-decanoylamino-3-morpholino-1-propanol is a novel cholesterol efflux accelerator. J Biol Chem 2005; 280:24515–24523.
Witting SR, Maiorano JN, Davidson WS. Ceramide enhances cholesterol efflux to apolipoprotein A-I by increasing the cell surface presence of ATP-binding cassette transporter A1. J Biol Chem 2003; 278:40121–40127.
Ghering AB, Davidson WS. Ceramide structural features required to stimulate ABCA1-mediated cholesterol efflux to apolipoprotein A-I. J Lipid Res 2006; 47:2781–2788.
Shayman JA, Lee L, Abe A, Shu L. Inhibitors of glucosylceramide synthase. Methods Enzymol 2000; 311:373–387.
Tamehiro N, Zhou S, Okuhira K et al. SPTLC1 binds ABCA1 to negatively regulate trafficking and cholesterol efflux activity of the transporter. Biochemistry 2008; 47:6138–6147.
Sano O, Kobayashi A, Nagao K et al. Sphingomyelin-dependence of cholesterol efflux mediated by ABCG1. J Lipid Res 2007; 48:2377–2384.
Jiang XC, Paultre F, Pearson TA et al. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2000; 20:2614–2618.
Nelson JC, Jiang XC, Tabas I et al. Plasma sphingomyelin and subclinical atherosclerosis: findings from the multi-ethnic study of atherosclerosis. Am J Epidemiol 2006; 163:903–912.
Dong J, Liu J, Lou B et al. Adenovirus-mediated overexpression of sphingomyelin synthases 1 and 2 increases the atherogenic potential in mice. J Lipid Res 2006; 47:1307–1314.
Schissel SL, Tweedie-Hardman J, Rapp JH et al. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J Clin Invest 1996; 98:1455–1464.
Jeong T, Schissel SL, Tabas I et al. Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase. J Clin Invest 1998; 101:905–912.
Arimoto I, Saito H, Kawashima Y et al. Effects of sphingomyelin and cholesterol on lipoprotein lipase-mediated lipolysis in lipid emulsions. J Lipid Res 1998; 39:143–151.
Bolin DJ, Jonas A. Sphingomyelin inhibits the lecithin-cholesterol acyltransferase reaction with reconstituted high density lipoproteins by decreasing enzyme binding. J Biol Chem 1996; 271:19152–19158.
Lee CY, Lesimple A, Denis M et al. Increased sphingomyelin content impairs HDL biogenesis and maturation in human Niemann-Pick disease type B. J Lipid Res 2006; 47:622–632.
Schuchmann EH, Desnick RJ. Niemann-Pick diseases Type A and B: Acid sphingomyelinase deficiencies. In: Scriver CR, ed. The Metabolic Bases of Inherited Disease, Vol. 2. New York: McGrawHill, 1995:2601–2624.
McGovern MM, Pohl-Worgall T, Deckelbaum RJ et al. Lipid abnormalities in children with types A and B Niemann Pick disease. J Pediatr 2004; 145:77–81.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Landes Bioscience and Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Worgall, T.S. (2011). Sphingolipid Synthetic Pathways are Major Regulators of Lipid Homeostasis. In: Cowart, L.A. (eds) Sphingolipids and Metabolic Disease. Advances in Experimental Medicine and Biology, vol 721. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-0650-1_9
Download citation
DOI: https://doi.org/10.1007/978-1-4614-0650-1_9
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-0649-5
Online ISBN: 978-1-4614-0650-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)